Omeprazole as a CYP2C19 marker in Chinese subjects: Assessment of its gene-dose effect and intrasubject variability

Journal of Clinical Pharmacology

Volumn 44, Issue 6, 2004, Pages 582-589

  Yin, Ophelia Q P ^a   Tomlinson, Brian ^a   Chow, Albert H L ^a   Waye, Mary M Y ^a   Chow, Moses S S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

CYP2C19; Gene dose effect; Omeprazole

Indexed keywords

5 HYDROXYOMEPRAZOLE; CYTOCHROME P450 2C19; MEPHENYTOIN; OMEPRAZOLE; OMEPRAZOLE SULFONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG FORMULATION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENE DOSAGE; GENE DOSE EFFECT; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION METABOLIC RATIO; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; ENZYME INHIBITORS; GENE DOSAGE; HUMANS; HYDROXYLATION; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REFERENCE VALUES;

EID: 2442694261     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004265702     Document Type: Article

References (34)

1. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishigchi K, Nishitora Y: CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001;18:721-727.
2. Skjelbo E, Gram LF, Brosen K: The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R ratio): a population study. Br J Clin Pharmacol 1993;35:331-334.
3. Breyer-Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier-Perey M, et al: Enantioselective amitryptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992;52:350-358.
4. Nielsen KK, Brosen K, Hansen MG, Gram LF: Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-527.
5. Bertilsson L, Henthorn TK, Sanz E, et al: Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-355.
6. Coller JK, Somogyi AA, Bochner F: Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica 1999;29:973-986.
7. Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-958.
8. Garcia-Barceló M, Chow LY, Chiu HFK, Wing WK, Lee DTS, Lam KL, et al: Frequencies of the defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4. Clin Chem 1999;45:2273-2274.
9. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-15422.
10. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598.
11. Xie HG, Kim RB, Wood AJ, Stein CM: Molecular basis of ethnic differences in drug dispositions and response. Annu Rev Pharmacol Toxicol 2001;41:815-850.
12. Setiabudy R, Chiba K, Kusaka M, Ishizaki T: Caution in the use of a 100mg dose of racemic mephenytoin for phenotyping Southeastern Oriental subjects. Br J Clin Pharmacol 1992;33:665-666.
13. Zhang Y, Blouin RA, McNamara P, Steinmetz J, Wedlund PJ: Limitation to the use of the urinary S/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991;31:350-352.
14. Chang M, Tybring G, Dahl M-L, Gotharson E, Sagar M, Seensalu R, et al: Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-518.
15. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L: Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-363.
16. Chiba K, Kobayashi K, Marabe K, Tani M, Kamataki T, Ishizaki T: Oxidation metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylations. J Pharmacol Exp Ther 1993;266:52-59.
17. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, et al: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993;36:521-530.
18. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-669.
19. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, et al: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′ -hydroxylation status. Clin Pharmacol Ther 1995;58:143-154.
20. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 1992;262:1195-1202.
21. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, et al: Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison of two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-653.
22. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-1030.
23. Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Qwen R, et al: Determination of CYP2C19 phenotype in black Americans: correlation with genotype. Clin Pharmacol Ther 1996;60:138-144.
24. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L: CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-551.
25. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA: Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 1987;15:277.
26. Kobayashi K, Chiba K, Sohn DR, Kato Y, Ishizaki T: Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. J Chromatogr 1992;579:299-305.
27. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
28. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
29. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizers in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64.
30. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studies in Caucasians and Orientals. Ther Drug Monit 1994;16:214-215.
31. Kim MJ, Bertino JS, Gaedigk A, Zhang Y, Sellers E, Nafziger AN: Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther 2002;72:192-199.
32. Xie HG, Huang ZH, Xiao ZS, Xiao ZS, He N, Zhou HH: Evidence for the effect of gender on activity of S-mephenytoin 4-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 1997;7:115-119.
33. Sviri S, Shpizen S, Leitersdorf E, et al: Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther 1999;65:275-282.
34. Laine K, Tybring G, Bertilsson L: No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 2000;68:151-159.